COPD affects far more than your lungs. While it starts as a respiratory disease, the chronic inflammation and low oxygen levels it creates ripple outward into your heart, muscles, bones, brain, and metabolism. About 37% of people with COPD also have metabolic syndrome, roughly 36% to 56% experience cognitive impairment, and up to half develop elevated blood pressure in the lungs. Understanding these body-wide effects helps explain why COPD so often comes with fatigue, weakness, mood changes, and other symptoms that seem unrelated to breathing.
The Respiratory System: Where It Starts
COPD damages the lungs in two main ways. In chronic bronchitis, the airways become inflamed and narrowed, producing excess mucus. In emphysema, the tiny air sacs where oxygen enters the blood are destroyed, reducing the surface area available for gas exchange. Most people with COPD have elements of both.
One of the central problems is air trapping. In healthy lungs, the tissue has enough elastic recoil to push air out during exhalation. In COPD, that springiness is lost, and the airways tend to collapse before you finish breathing out. The result is that stale air gets trapped inside the lungs, and each new breath stacks on top of air that was never fully exhaled. This is called hyperinflation, and it gets dramatically worse during exercise or any activity that speeds up your breathing rate, because there’s even less time for each exhale to finish. Over time, the lungs remain chronically overinflated, the diaphragm flattens, and breathing requires more effort just to move air in and out.
The downstream consequence is that less oxygen reaches your blood and more carbon dioxide builds up. These gas exchange problems are the root cause of many of the system-wide effects described below.
Cardiovascular System
COPD places a significant burden on the heart, particularly the right side. When lung tissue is destroyed and oxygen levels drop, the blood vessels in the lungs constrict and remodel, raising the pressure the right side of the heart has to pump against. This condition, pulmonary hypertension, is found in 20% to 91% of COPD patients depending on disease severity, with large studies of advanced COPD patients placing the number around 50%. Over time, the right ventricle thickens and enlarges as it struggles against this rising resistance, a condition called cor pulmonale.
Hyperinflated lungs compound the problem physically. The overexpanded lungs compress the heart between them, making it harder for the right ventricle to fill with blood between beats. This reduces the amount of blood the heart can pump with each contraction, which is one reason people with COPD feel exhausted and short of breath during activities that wouldn’t have winded them before. The 2025 guidelines from the Global Initiative for Chronic Obstructive Lung Disease added a new section on cardiovascular risk specifically because heart disease is so common in this population, and often goes undiagnosed.
Systemic Inflammation
COPD isn’t just local inflammation in the airways. It triggers a body-wide inflammatory response that acts as a connecting thread between the lungs and nearly every other affected system. Two key inflammatory signals, interleukin-6 (IL-6) and C-reactive protein (CRP), circulate at elevated levels in the blood of COPD patients. In one study, the median CRP level in COPD patients was 5.50 mg/L, already above the normal upper limit of 5. IL-6 levels ran at 8.80 pg/mL, also above the normal ceiling of 7.
These aren’t just lab curiosities. Higher IL-6 and CRP levels correlate strongly with more frequent flare-ups, worse breathing test results, and greater symptom burden. IL-6 in particular showed a striking correlation of 0.852 with the frequency of acute exacerbations over a year. This persistent low-grade inflammation is what drives muscle wasting, bone loss, metabolic disruption, and cognitive decline in COPD patients.
Skeletal Muscles
About 21.6% of people with COPD develop sarcopenia, a condition where muscles progressively shrink and weaken. This affects both the limbs and the respiratory muscles themselves, creating a vicious cycle: weaker breathing muscles make airflow worse, and weaker leg muscles make even short walks exhausting, which leads to more inactivity and further muscle loss.
The biology behind this muscle wasting involves several overlapping processes. Chronic inflammation redirects amino acids away from muscles and toward the liver, where they’re used to produce emergency proteins. At the same time, inflammatory signals like TNF-alpha activate a protein-disposal system in muscle cells that breaks down muscle fibers faster than they can be rebuilt. Studies show that people with COPD who have significant muscle loss have markedly higher TNF-alpha and IL-6 levels, and those levels correlate directly with lower grip strength and less muscle mass.
Hormonal changes make things worse. Testosterone, insulin-like growth factor 1 (IGF-1), and DHEA, all hormones critical for building and maintaining muscle, are significantly lower in COPD patients than in healthy people of the same age. These hormone levels drop further as IL-6 rises, and the ratio of IL-6 to DHEA increases in step with the severity of muscle wasting. Low oxygen and high carbon dioxide levels in the blood, physical inactivity, poor nutrition, and long-term steroid use all pile on additional stress to the muscles.
Bones
Osteoporosis is a common but often overlooked complication of COPD. Chronic inflammation, reduced physical activity, low hormone levels, nutritional deficiencies, and corticosteroid use all weaken bones over time. Many of these are the same factors driving muscle loss, which is why the two conditions frequently appear together.
Inhaled corticosteroids, a mainstay of COPD treatment, add a dose-dependent layer of risk. At doses of 500 micrograms per day or higher (in fluticasone-equivalent terms), the risk of osteoporosis and fractures rises measurably. At very high doses of 1,600 micrograms per day, fracture risk increases by about 80%. Long-term use beyond 24 months also elevates the risk of fractures and recurrent bone-related complications. Elderly patients and women appear to be especially vulnerable. Lower doses still carry some increased risk compared to COPD patients not using inhaled steroids, though the effect is smaller.
Brain and Cognitive Function
Cognitive impairment is far more common in COPD than most people realize. Depending on the testing method used, roughly 36% to 56% of COPD patients show some degree of cognitive decline. Among those on long-term oxygen therapy, the number climbs to about 70%, and 40% of those patients show progressive worsening over just one year.
Chronic low oxygen damages the brain through at least three pathways. It suppresses the production of proteins that nerve cells need to communicate with each other. It triggers inflammation and oxidative stress directly in brain tissue. And it impairs blood flow to the brain by damaging the lining of blood vessels. The cognitive domains most affected are verbal memory and executive function, the ability to plan, organize, and shift between tasks. These changes can make it harder to manage medications, follow treatment plans, or handle the daily logistics of living with a chronic illness.
Metabolism and Blood Sugar
A meta-analysis of over 54,000 COPD patients found that 37% met the criteria for metabolic syndrome, a cluster of conditions including high blood pressure, elevated blood sugar, excess abdominal fat, and abnormal cholesterol. That rate is notably higher than the 12.5% to 31.4% seen in the general population. The most common components were high blood pressure (58% of patients) and increased waist circumference (51%). Elevated blood glucose, suggesting insulin resistance, appeared in 43%.
Among COPD patients specifically, diabetes prevalence ranges from 3% to 12% overall, but in one large study of nearly 200,000 participants over age 40, 20% of those with COPD had diabetes and 25% were obese. The risk of developing diabetes rises with worsening lung function, particularly in the more advanced stages of the disease. Cardiovascular disease, type 2 diabetes, and high blood pressure appear across all severity levels of COPD, and they influence hospitalization and death rates independently of how obstructed the airways are.
Mental Health
Depression and anxiety are strikingly common in COPD and tend to worsen as the disease progresses. Among outpatients, anxiety rates range from 13% to 46%, while inpatients reach up to 55%. In end-stage COPD, anxiety has been reported in up to 75% of patients. Depression affects 27% to 40% of people with stable COPD, but during acute flare-ups that number can spike as high as 86%.
People with COPD have nearly double the risk of developing depression compared to matched controls without the disease, with incidence rates of 11.4 versus 5.7 per 1,000 person-years. This isn’t simply a reaction to living with a chronic illness. The same systemic inflammation, chronic hypoxia, and hormonal disruption that damage muscles and bones also affect brain chemistry. Breathlessness itself triggers anxiety in a self-reinforcing loop: feeling short of breath causes panic, which speeds up breathing, which worsens air trapping, which makes breathlessness worse.